May 31, 2024

Bittersweet week as we bid farewell to Andreanne Sannajust. She has been with us since 2022, first as an undergrad student and then as a lab assistant. In addition to being a talented, meticulous and dedicated scientist, she has also become a fantastic teacher - here she is in the picture (sitting down) with just a few of the undergraduate students she has trained over the past year. And while we will all miss Andreanne dearly, we are incredibly proud and excited for her as she heads to the University of Colorado for medical school. Go get them!

April 6, 2024

The Soragni Lab will be present in force at the 2024 Annual AACR Meeting in San Diego! Luda will present a poster on our chemoradiation platform for head and neck cancer organoids on Sunday. On Monday, Alice will chair a session on organoids and talk about heterogeneity and genetic diversity in patient-derived organoids from rare benign and malignant tumors while Sara will be presenting a poster on protein aggregation in ovarian cancer.

March 31, 2024

The lab is very grateful to the C2C team which is spearheaded by a group of fantastic teen advocates! Their tireless efforts in raising funds to support our lab research on pediatric sarcomas have so far allowed us to test more patient samples, quickly and robustly.

February 27, 2024

Huge congratulations to Sara who won the AACR-Margaret Foti Foundation Scholar-in-Training Award to attend the 2024 AACR Annual Meeting in San Diego! Dr. Sartini will present her work on p53 aggregation in ovarian cancer on April 8, 2024 from 1:30 PM to 5:00 PM in session PO.MCB11.01 (Poster 3027/25).

February 1, 2024

Our very first clinical trial that leverages patient-derived tumor organoids in osteosarcoma is officially open and enrolling! PREMOST, An Organoid-based Functional Precision Medicine Trial in Osteosarcoma (NCT06064682) is open to patients of any age with either a suspect osteosarcoma diagnosis (Arm 1) or recurrent/metastatic osteosarcoma (Arm 2). We will test feasibility to develop organoids from these cases and determine the prognostic power of the assay as well as return results to the clinic through our sarcoma tumor board.